Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders (2013 - 2026)
Tandem Diabetes Care (TNDM) posted Net Income towards Common Stockholders of -$20.4 million for Q1 2026, down 3656.91% on a QoQ basis from -$543000.0 in Q4 2025, and up 84.38% year-over-year from -$11.1 million in Q1 2025.
Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$20.4 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 84.38% year-over-year to -$20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.5 million (up 48.59% YoY) and the FY2025 annual result came in at -$204.7 million, down 113.18% from the prior year.
- Net Income towards Common Stockholders was -$20.4 million for Q1 2026 at Tandem Diabetes Care, down from -$543000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $755000.0 in Q4 2024 and bottomed at -$130.6 million in Q1 2025.
- A 5-year average of -$37.5 million and a median of -$30.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 951.88% — and 2024, when it soared 102.52%.
- Tandem Diabetes Care's Net Income towards Common Stockholders stood at -$15.9 million in 2022, then slumped by 88.58% to -$30.0 million in 2023, then jumped by 102.52% to $755000.0 in 2024, then tumbled by 171.92% to -$543000.0 in 2025, then plunged by 3656.91% to -$20.4 million in 2026.
- Business Quant data shows TNDM's Net Income towards Common Stockholders at -$20.4 million in Q1 2026, -$543000.0 in Q4 2025, and -$21.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Tandem Diabetes Care | 1.17 Bn | 597.96 Mn | 136.79 Mn | -20.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.40 Mn |
| Dec 31, 2025 | -543,000.00 |
| Sep 30, 2025 | -21.17 Mn |
| Jun 30, 2025 | -52.42 Mn |
| Mar 31, 2025 | -130.60 Mn |
| Dec 31, 2024 | 755,000.00 |
| Sep 30, 2024 | -23.21 Mn |
| Jun 30, 2024 | -30.81 Mn |
| Mar 31, 2024 | -42.73 Mn |
| Dec 31, 2023 | -29.97 Mn |
| Sep 30, 2023 | -32.96 Mn |
| Jun 30, 2023 | -35.75 Mn |
| Mar 31, 2023 | -123.90 Mn |
| Dec 31, 2022 | -15.89 Mn |
| Sep 30, 2022 | -48.95 Mn |
| Jun 30, 2022 | -15.05 Mn |
| Mar 31, 2022 | -14.74 Mn |
| Dec 31, 2021 | 10.76 Mn |
| Sep 30, 2021 | 5.75 Mn |
| Jun 30, 2021 | 4.00 Mn |